

MOXIF

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory Only

Abbreviated Prescribing information for MOXIF [Moxifloxacin Eye Drops I.P.]
[Please refer the complete prescribing information available at www.torrentpharma.com]

PHARMACOLOGICAL PROPERTIES:

MECHANISM OF ACTION: Moxifloxacin is a member of the fluoroquinolone class of anti-infective drugs. The mechanism of action for quinolones, including moxifloxacin, is different from that of macrolides, aminoglycosides, or tetracyclines. Therefore, moxifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to moxifloxacin.

INDICATIONS: It is indicated for Bacterial Conjunctivitis.

DOSAGE AND ADMINISTRATION: Instil one drop in the affected eye 3 times a day for 7 days. Moxifloxacin ophthalmic solution is for topical ophthalmic use.

CONTRAINDICATION: Moxifloxacin ophthalmic solution is contraindicated in patients with a history of hypersensitivity to moxifloxacin, to other quinolones, or to any of the components in this medication.

WARNINGS & PRECAUTIONS: This drug may cause low blood sugar and mental health related side effects. If an allergic reaction to moxifloxacin occurs, discontinue use of the drug. Serious acute hypersensitivity reactions may require immediate emergency treatment. As with other anti-infectives, prolonged use may result in overgrowth of non-susceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Patients should be advised not to wear contact lenses if they have signs or symptoms of bacterial conjunctivitis.

DRUG INTERACTIONS: In vitro studies indicate that moxifloxacin does not inhibit CYP3A4, CYP2D6, CYP2C9, CYP2C19, or CYP1A2, indicating that moxifloxacin is unlikely to alter the pharmacokinetics of drugs metabolized by these cytochrome P450 isozymes.

ADVERSE REACTIONS: Conjunctivitis, decreased visual acuity, dry eye, keratitis, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, subconjunctival hemorrhage, tearing, fever, increased cough, infection, otitis media, pharyngitis, rash, and rhinitis.

MARKETED BY:

TORRENT
PHARMA

Torrent Pharmaceuticals Limited.

IN/MOXIF 0.5%w/v/JUN 2026/01/ABPI

(Additional information is available on request)